Talha Badar, Hematology/Oncology Specialist at Mayo Clinic shared a post on X:
“1) Adverse risk AML: Outcomes, Transplant and Perspectives
• Inv(3)/EVI1
•TP53-mutated
• Monosomal karyotype (MK)
• Complex karyotype (CK)
• Monosomy –7
Without transplant – median OS ~4–12 months
Ref: Döhner et al. ELN 2022 recommendations; Breems et al. Monosomal Karyotype; Grimwade et al. Cytogenetics AML; Lugthart et al. inv(3) AML; Fang et al. Complex Karyotype AML
2) inv(3)/EVI1 AML
GATA2 enhancer hijack – MECOM overexpression
Clinical clue: Thrombocytosis in AML –rule out inv(3)
Outcomes:
• CR ~30–40%
• Median OS ~5–8 mo
• High post-SCT relapse (~65–70%)
Early transplant critical
Ref: Lugthart et al. inv(3) AML; Döhner et al. ELN 2022 recommendations
3) TP53-mutated AML: COMMAND data
Real-world outcomes:
• Median OS ~7–8.5 mo (regardless of induction)
• CR/CRi ~34%
• Only ~18% reach transplant
Key point:
Allo-SCT = ONLY factor improving survival
TP53 AML — therapeutic reality
APR-246 + aza – Phase III negative
Magrolimab – ENHANCE trials negative
HMA+VEN – responses (~30–40%) but no OS benefit
Take-home:
Induction ≠ survival driver
Transplant is the only lever
Ref: Zeremski et al. APR-246 Phase III; Gilead Sciences Magrolimab ENHANCE; Badar et al. VEN+HMA TP53 AML
COMMAND Consortium:
[B1] Badar et al. TP53 AML frontline (AJH 2022)
[B2] Badar et al. TP53 allo-SCT outcomes (Leukemia 2023)
[B3] Badar et al. TP53 R/R AML (ASH2023)
[B4] Badar et al. VEN+HMA TP53 AML (BCJ 2024, 2025)
4) Monosomal Karyotype (MK)
Definition: ≥2 monosomies OR 1 monosomy + structural abnormality
Outcomes:
• Median OS ~4–7 mo
• 4-year OS ~4% (!)
Strongest cytogenetic predictor of death
Urgent transplant
Ref: Breems et al. Monosomal Karyotype
5) Complex Karyotype (CK)
Not all CK is equal:
• CK without MK – OS ~10–14 mo
• CK + MK – OS ~4–7 mo
TP53 co-mutation in ~70–80%
Always pair cytogenetics + molecular testing
Ref: Fang et al. Complex Karyotype AML; Breems et al. Monosomal Karyotype; Döhner et al. ELN 2022 recommendations
6) Monosomy – 7
Hallmark of therapy-related AML
Outcomes:
• Isolated: OS ~6–10 mo
• With CK/MK – behaves like MK (~4–6 mo)
Seen in germline predisposition, pediatric AML
Transplant in CR1
Ref: Grimwade et al. Cytogenetics AML; Breems et al. Monosomal Karyotype
7) Allo-SCT across subgroups
Consistent finding:
Transplant prolongs survival in all five groups
But:
• Relapse rates ~50–80%
• Outcomes still poor
Still the only curative strategy
What improves transplant outcomes?
- MRD negativity (strongest factor)
- CR1 transplant
- Day 100 CR + cGVHD
MAC vs RIC – no clear winner
MUD ≈ MSD
Don’t delay transplant.
Ref: Badar et al. TP53 allo-SCT outcomes; Breems et al. Monosomal Karyotype; Lugthart et al. inv(3) AML; Fang et al. Complex Karyotype AML
8) Adverse risk AML/ alloHCT
Across all of these high-risk AML subgroups, prognosis remains dismal. Despite multiple therapeutic advances, allogeneic stem cell transplant remains the only intervention that consistently improves survival.
Bottom line
Transplant vs no transplant = months vs years
But:
• High relapse
• Novel agents not yet changing survival
Strategy:
• Early SCT referral
• MRD monitoring
• Trial enrollment
• Honest goals-of-care”
Other articles featuring Talha Badar on OncoDaily.